Compositions and methods relating to the treatment of diseases

{
  "publication_number": "US2018273597A1",
  "country": "US",
  "kind": "A1",
  "title": "Compositions and methods relating to the treatment of diseases",
  "abstract": "A compressible adjunct is used with a surgical instrument. The compressible adjunct includes a hollow fibrous construct and a core fibrous construct housed within the hollow fibrous construct, wherein the hollow fibrous construct comprises at least one biocompatible material that has experienced at least one transition from a more ordered phase to a less ordered phase in response to heating the hollow fibrous construct to a predetermined temperature.",
  "claims": [
    "1. A method for the treatment and/or prophylaxis of a condition where an enhancement of a Th1-mediated immune response and suppression of a Th2/Th17-mediated immune response are desired, said method comprising the step of: (i) administering to a subject in need thereof a therapeutically effective amount of at least one interferon alpha subtype selected from IFN-α10, IFN-α14 and a hybrid thereof, wherein the hybrid includes the primary interferon receptor binding sites of IFN-α10 and IFN-α14. 2. The method as claimed in claim 1 wherein the condition where an enhancement of a Th1-mediated immune response and suppression of a Th2/Th17-mediated immune response are desired is selected from the group consisting of an autoimmune disease, an inflammatory disease, allergy or an associated allergic condition and cancer. 3. The method as claimed in claim 2 wherein the inflammatory disease is inflammatory bowel disease, optionally wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease. 4. (canceled) 5. The method as claimed in claim 2 wherein the condition where an enhancement of a Th1-mediated immune response and suppression of a Th2/Th17-mediated immune response are desired is allergy or an associated allergic condition suitably food allergy or an associated condition or wherein the cancer is hepatic cell cancer, lung cancer, non-small cell lung cancer, ovarian cancer, breast cancer, skin cancer, melanoma, genitourinary cancer, prostate cancer, renal cell cancer, or bladder cancer. 6. (canceled) 7. The method as claimed in claim 1 wherein the method includes a step of administering to the subject a therapeutically effective amount of a vaccine composition for treatment or prophylaxis of the condition where an enhancement of a Th1-mediated immune response and suppression of a Th2/Th17-mediated immune response are desired. 8. The method as claimed in claim 7 wherein the vaccine composition comprises at least one allergen capable of mediating a Th2/Th17 immune response, optionally wherein the at least one allergen is a food allergen or a tumour antigen, for example tumour specific antigen or tumour-associated antigen. 9. (canceled) 10. (canceled) 11. (canceled) 12. The method as claimed in claim 1 wherein the at least at least one interferon alpha subtype is IFN-α10, IFN-α14, or an IFN-α10 IFN-α14 hybrid wherein the hybrid includes the primary interferon receptor binding sites of IFN-α10 and IFN-α14 and has improved binding to interferon receptor 1 and interferon receptor 2 in comparison to IFN-α10 or IFN-α14. 13. The method as claimed in claim 1 wherein the hybrid comprises the amino acid sequence set forth by SEQ ID NO: 1 or a fragment or variant thereof. 14. (canceled) 15. (canceled) 16. The method as claimed in claim 1 wherein the hybrid comprises at least one, at least two, at least three, at least four or at least five mutations selected from amino acids at positions 94, 101, 102, 109 or 144. 17. An interferon alpha subtype hybrid comprising the primary interferon receptor binding sites of IFN-α10 and IFN-α14. 18. An interferon alpha subtype as claimed in claim 17 comprising the amino acid sequence of SEQ ID NO: 1 or a fragment or variant thereof. 19.- 48. (canceled) 49. A composition comprising: (i) a vaccine; and (ii) at least one interferon alpha subtype selected from IFN-α10, IFN-α14 and a hybrid thereof wherein the hybrid includes the primary interferon receptor binding sites of IFN-α10 and IFN-α14. 50. (canceled) 51. (canceled) 52. (canceled) 53. The composition as claimed in claim 49 wherein the at least one interferon alpha subtype is IFN-α10, IFN-α14, or an IFN-α10 IFN-α14 hybrid wherein the hybrid includes the primary interferon receptor binding sites of IFN-α10 and IFN-α14 and has improved binding to interferon receptor 1 and interferon receptor 2 in comparison to IFN-α10 or IFN-α14. 54. (canceled) 55. The composition as claimed in claim 49 wherein the hybrid comprises the amino acid sequence set forth by SEQ ID NO: 1 or a fragment or variant thereof. 56.- 63. (canceled) 64. A method for the treatment and/or prophylaxis of a condition mediated by enhanced expression of IL-17, said method comprising the step of: (i) administering to a subject in need thereof a therapeutically effective amount of at least one interferon alpha subtype selected from IFN-α10, IFN-α14 and a hybrid thereof wherein the hybrid includes the primary interferon receptor binding sites of IFN-α10 and IFN-α14. 65. (canceled) 66. (canceled) 67. (canceled) 68. The method as claimed in claim 64 wherein the at least at least one interferon alpha subtype is IFN-α10, IFN-α14, or an IFN-α10 IFN-α14 hybrid wherein the hybrid includes the primary interferon receptor binding sites of IFN-α10 and IFN-α14 and has improved binding to interferon receptor 1 and interferon receptor 2 in comparison to IFN-α10 or IFN-α14. 69. The method as claimed in claim 64 wherein the hybrid comprises the amino acid sequence set forth by SEQ ID NO: 1 or a fragment or variant thereof. 70. (canceled) 71. (canceled) 72. The method as claimed in claim 64 wherein the hybrid comprises at least one, at least two, at least three, at least four or at least five mutations selected from amino acids at positions 94, 101, 102, 109 or 144. 73.- 90. (canceled)"
  ],
  "description_excerpt": "The present invention relates to surgical instruments and, in various arrangements, to surgical stapling and cutting instruments and staple cartridges for use therewith that are designed to staple and cut tissue.\n\nThe features of the various embodiments are set forth with particularity in the appended claims. The various embodiments, however, both as to organization and methods of operation, together with advantages thereof, may best be understood by reference to the following description, taken in conjunction with the accompanying drawings as follows:\n\nFIG. 1 is a perspective view of a surgical stapling and severing instrument comprising a handle, a shaft extending from the handle, and an end effector extending including an anvil and a staple cartridge;\n\nFIG. 2 is a perspective view of a wedge sled of a staple cartridge of the surgical stapling and severing instrument of FIG. 1;\n\nFIG. 3 is a perspective view of a two-piece knife and firing bar (“E-beam”) of the surgical stapling and severing instrument of FIG. 1;\n\nFIG. 4 is a longitudinal cross-sectional view of an anvil in a closed position, a staple cartridge comprising a rigid support portion, and a compressible adjunct illustrated with staples being moved from an unfired position to a fired position during a firing sequence;\n\nFIG. 5 is another cross-sectional view of the anvil and the staple cartridge of FIG. 4 illustrating the anvil in an open position after the firing sequence has been completed;\n\nFIG. 6 is a side view of a compressible adjunct and a staple cartridge in accordance with at least one embodiment;",
  "cpc": [
    "C07K 14/56",
    "A61K 38/212",
    "A61K 39/0011",
    "A61K 39/35",
    "A61P 29/00",
    "A61P 35/00",
    "A61P 37/00",
    "A61P 37/08",
    "C07K 19/00",
    "C07K 2319/00"
  ],
  "ipc": [
    "A61K 38/21",
    "A61K 39/00",
    "A61K 39/35",
    "C07K 14/56",
    "C07K 19/00"
  ],
  "assignees": [
    "Alfacyte Ltd"
  ],
  "inventors": [
    "William Stimson"
  ],
  "filing_date": "2016-09-14",
  "publication_date": "2018-09-27",
  "priority_date": "2015-09-15",
  "application_number": "US-201615760200-A",
  "family_id": "57003529",
  "cited_by_count": 868,
  "citations": [
    "WO2014037717A1",
    "US9522173B2"
  ]
}